Eli Lilly’s Checkmate in the GLP-1 Arena
Eli Lilly, ever the pragmatist, has unveiled data from trials that suggest its oral GLP-1 drug, orforglipron, may well be the phoenix rising from the ashes of previous contenders. While Novo Nordisk’s Rybelsus, the first oral GLP-1 treatment, was celebrated as a breakthrough in 2019, Lilly’s efforts have been met with a blend of skepticism and quiet confidence. The results, however, speak louder than the murmurs of doubt.